Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22510863 | 0.97 | TMEM97 (0.51) | TMEM97SIGMAR1KDM4ETP53BRAF | |
| SCHEMBL20415345 | 0.91 | CYP3A4 (0.46) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL20415226 | 0.89 | CES2 (0.44) | KDM4ECES2CES1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20415343 | 0.88 | KMT2A (0.50) | TMEM97SIGMAR1KDM4EBRAFALDH1A1 | |
| SCHEMBL20415257 | 0.88 | KMT2A (0.48) | TMEM97SIGMAR1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL20415209 | 0.87 | TMEM97 (0.47) | TMEM97SIGMAR1KDM4ETP53G6PC1 | |
| SCHEMBL22510885 | 0.87 | KDM4E (0.50) | TMEM97SIGMAR1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL20415256 | 0.85 | EGFR (0.49) | BRAFCES2CES1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20415223 | 0.84 | TMEM97 (0.50) | TMEM97SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL20415218 | 0.83 | TMEM97 (0.47) | TMEM97SIGMAR1KDM4ETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397652-A2 | 3-(PHENYL)-2-(AMINOMETHYL)-1-PHENYL-2-PROPEN-1-ONE DERIVATIVES AS INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR FOR TREATING PROSTATE CANCER | The Regents of the University of California (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-110325508-B | Inhibitors of the N-terminal domain of androgen receptor | 加利福尼亚大学董事会 | 2023-06-30 | — | — | CN | disclosed |
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| WO-2018136792-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | AR, BRDT, NR5A1 | TMEM97 1389/4885SIGMAR1 1480/4885KDM4E 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.